Cancer treatment-related bone disease

Theresa Guise, Sue A. Brown

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Bone health may be impaired in many patients being treated for cancer. Primary tumors that reside in or form metastases to bone can result in compromised skeletal integrity. It has also been increasingly recognized that patients undergoing therapies for treatment of cancer are at higher risk of bone loss. These include androgen-deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, among others. Hypogonadism induced by many of these cancer treatments results in bone loss and increases the risk of osteoporosis and fractures. Progress has been made in identifying the role of oral and intravenous bisphosphonates to prevent bone loss in these patients. This review discusses bone loss associated with cancer treatments, with a focus on breast cancer, prostate cancer, and survivors of childhood malignancies.

Original languageEnglish (US)
Pages (from-to)47-60
Number of pages14
JournalCritical Reviews in Eukaryotic Gene Expression
Volume19
Issue number1
StatePublished - 2009
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Bone Diseases
Bone and Bones
Prostatic Neoplasms
Neoplasms
Breast Neoplasms
Therapeutics
Aromatase Inhibitors
Hypogonadism
Diphosphonates
Androgens
Osteoporosis
Survivors
Neoplasm Metastasis
Health

Keywords

  • Bone metastases
  • Cancer
  • Hypogonadism
  • Osteoporosis
  • Treatment-related bone loss

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Cancer treatment-related bone disease. / Guise, Theresa; Brown, Sue A.

In: Critical Reviews in Eukaryotic Gene Expression, Vol. 19, No. 1, 2009, p. 47-60.

Research output: Contribution to journalArticle

@article{349fb56427b4432698444a54c4976016,
title = "Cancer treatment-related bone disease",
abstract = "Bone health may be impaired in many patients being treated for cancer. Primary tumors that reside in or form metastases to bone can result in compromised skeletal integrity. It has also been increasingly recognized that patients undergoing therapies for treatment of cancer are at higher risk of bone loss. These include androgen-deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, among others. Hypogonadism induced by many of these cancer treatments results in bone loss and increases the risk of osteoporosis and fractures. Progress has been made in identifying the role of oral and intravenous bisphosphonates to prevent bone loss in these patients. This review discusses bone loss associated with cancer treatments, with a focus on breast cancer, prostate cancer, and survivors of childhood malignancies.",
keywords = "Bone metastases, Cancer, Hypogonadism, Osteoporosis, Treatment-related bone loss",
author = "Theresa Guise and Brown, {Sue A.}",
year = "2009",
language = "English (US)",
volume = "19",
pages = "47--60",
journal = "Critical Reviews in Eukaryotic Gene Expression",
issn = "1045-4403",
publisher = "Begell House Inc.",
number = "1",

}

TY - JOUR

T1 - Cancer treatment-related bone disease

AU - Guise, Theresa

AU - Brown, Sue A.

PY - 2009

Y1 - 2009

N2 - Bone health may be impaired in many patients being treated for cancer. Primary tumors that reside in or form metastases to bone can result in compromised skeletal integrity. It has also been increasingly recognized that patients undergoing therapies for treatment of cancer are at higher risk of bone loss. These include androgen-deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, among others. Hypogonadism induced by many of these cancer treatments results in bone loss and increases the risk of osteoporosis and fractures. Progress has been made in identifying the role of oral and intravenous bisphosphonates to prevent bone loss in these patients. This review discusses bone loss associated with cancer treatments, with a focus on breast cancer, prostate cancer, and survivors of childhood malignancies.

AB - Bone health may be impaired in many patients being treated for cancer. Primary tumors that reside in or form metastases to bone can result in compromised skeletal integrity. It has also been increasingly recognized that patients undergoing therapies for treatment of cancer are at higher risk of bone loss. These include androgen-deprivation therapy for prostate cancer and aromatase inhibitor therapy for breast cancer, among others. Hypogonadism induced by many of these cancer treatments results in bone loss and increases the risk of osteoporosis and fractures. Progress has been made in identifying the role of oral and intravenous bisphosphonates to prevent bone loss in these patients. This review discusses bone loss associated with cancer treatments, with a focus on breast cancer, prostate cancer, and survivors of childhood malignancies.

KW - Bone metastases

KW - Cancer

KW - Hypogonadism

KW - Osteoporosis

KW - Treatment-related bone loss

UR - http://www.scopus.com/inward/record.url?scp=58849119154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849119154&partnerID=8YFLogxK

M3 - Article

C2 - 19191756

AN - SCOPUS:58849119154

VL - 19

SP - 47

EP - 60

JO - Critical Reviews in Eukaryotic Gene Expression

JF - Critical Reviews in Eukaryotic Gene Expression

SN - 1045-4403

IS - 1

ER -